🇺🇸 TRIPHOSPHATE in United States

123 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 20 reports (16.26%)
  2. Platelet Count Decreased — 15 reports (12.2%)
  3. Diarrhoea — 14 reports (11.38%)
  4. Off Label Use — 13 reports (10.57%)
  5. Pneumonia — 12 reports (9.76%)
  6. Drug Ineffective — 11 reports (8.94%)
  7. Pruritus — 11 reports (8.94%)
  8. Anaemia — 9 reports (7.32%)
  9. Drug Eruption — 9 reports (7.32%)
  10. Toxicity To Various Agents — 9 reports (7.32%)

Source database →

TRIPHOSPHATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TRIPHOSPHATE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for TRIPHOSPHATE in United States?

Marketing authorisation holder not available in our data.